Criteria for Diagnosing Alzheimer Disease and the Role of Testing

Focusing on the diagnosis of Alzheimer disease, the panel discusses key diagnostic criteria, testing practices, and the role of genetic testing.

EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease

EP: 3.Genetic Aspects of Alzheimer Disease

EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease

Now Viewing

EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing

EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

EP: 9.Clinical Decision-Making for Alzheimer Disease Management

EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease

EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease

EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

1. Discuss the key diagnostic criteria for AD. How do you differentiate between AD and other forms of dementia during the diagnostic process? 
2. What tests might providers order to help establish a diagnosis of AD? [e.g., biomarker, genetic, and neuroimaging tests.] 
3. Do you consider the results of genetic testing when selecting among available treatment options for patient with AD?

Related Videos

Related Content

Advertisement

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

Brooke McCormick

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Related Content

Advertisement

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

Brooke McCormick

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.